Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that on 21 May 2026 it bought back 87,300 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$5.30 to HK$5.31 per share. The volume-weighted average repurchase price was HK$5.303265, bringing the total cash outlay to HK$0.46 million.

Following the transaction: • Issued shares (excluding treasury shares) decreased by 0.011 % to 784.26 million. • Treasury shares increased to 7.50 million, while the company’s total issued shares remained unchanged at 791.76 million.

Repurchases are being executed under the mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulative repurchases under this mandate now total 4.48 million shares, equivalent to 0.568 % of the issued share base on the mandate’s reference date.

Under Hong Kong listing rules, Jacobio is subject to a moratorium on issuing new shares or transferring treasury shares until 20 June 2026. The company confirmed that the buyback complied with all relevant Main Board requirements.